Molecular therapy company: Denali Therapeutics Inc. (DNLI)

Denali Therapeutics Inc. (NASDAQ: DNLI) was incorporated in Delaware in 2013 and is headquartered in Southern San Francisco, California, USA. It has 176 full-time employees. It is a biopharmaceutical company that discovers and develops drugs to combat neurodegeneration. disease.

Denali Therapeutics

Denali Therapeutics Inc. (DNLI):

To treat Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases, Denali Therapeutics, Inc. is applying in-depth scientific and drug development expertise to discover effective molecular therapies and designing a proprietary technology platform, Provide biological therapy to the brain. Recent genetic studies have revealed the potential biology of neurodegenerative diseases and potential drug targets, providing patients with better choices, similar to how genetic studies have changed the field of oncology.

The core principles of Denali Therapeutics:

  1. Identifying and selecting targets based on proven genetic drivers of neurodegeneration is the core principle of Denali Therapeutics’ strategy.
  2. The second core principle of the company’s strategy is to develop drugs that can effectively cross the blood-brain barrier (BBB) ​​and target the brain. Denali Therapeutics has designed a proprietary BBB platform technology, which the companies believe will enable its candidate products to have therapeutically needed concentrations in the brain.
  3. The third core principle of the Denali Therapeutics strategy is to develop and use biomarkers so that patients can better choose and demonstrate the goals and approaches of candidate products.

Denali Therapeutics has a team of experienced and dedicated scientists and drug developers. The company believes that it can successfully improve the lives of patients and their families.

Denali Therapeutics started operations in May 2015 and recently started the company’s first clinical trial.

Denali Therapeutics Inc. (DNLI) investment:

Denali Therapeutics Inc. (NASDAQ: DNLI) landed on Nasdaq on 12/8/2017 IPO with an issue price of US$18, issuing 13,888,888 shares, raising US$249,999,984.00, stock code: DNLI.

Notify of
Inline Feedbacks
View all Intels

The Big Three of French Banks: Credit Agricole SA (CRARY) (1894)

Development stage medical device company: Hancock Jaffe Laboratories (HJLI) (1999)